For Men With BPH
FloStent™ System



RIVER MARK

RAPID-3 STUDY: investigational clinical study using the FloStent™* to treat symptoms associated with Benign Prostatic Hyperplasia (BPH)

Who can Join?

- Men aged 45 years or older
- Currently suffering from symptoms (frequent urination, painful or difficulty in urination, inability to empty bladder completely, etc.) associated with BPH
- Willingness to attend regular visits with the study doctors

What is the FloStent™*?

- Innovative, minimally invasive medical device
- Small, nitinol implant designed to relieve symptoms associated with BPH
- Implant procedure can be conducted in urologist's office or surgery center

What To Expect

- The RAPID-3 Study involves a procedure performed by a trained and certified urologist.
- The purpose of this study is to evaluate the safety and efficacy (effectiveness) of the FloStent™* in relieving symptoms of associated with BPH.
- According to available FloStent™* data, most men feel relief from BPH symptoms and are able to resume common lifestyle activities shortly after the procedure.
- Most previous FloStent™* recipients continue sexual function without burning or irritation.

Why Participate?

- Your participation may contribute to the medical field's knowledge of BPH and how best to treat it.
- The RAPID-3 Study will provide data for FDA review that may allow the FloStent™* to be further used in the United States.
- Your participation may help you and other BPH patients.

The study doctor will explain the possible risks and benefits involved with your study participation. There is no cost to join the RAPID-3 Study, undergo the procedure, or attend study-related visits. The Study is Approximately 1 year with 7 visits, and an additional 4 years (4 visits) of long-term up follow up. You may or may not be assigned to the stent implant group. If assigned to the stent implant group, you will receive the FloStent™*. If not assigned to the stent implant group, you will have the option to receive it later in the study. Your doctor will be able to explain this option to you.

SCAN CODE FOR MORE INFORMATION

CONTACT INFORMATION

The Sponsor of this study is Rivermark Medical.
If you are interesting learning more or participating in the RAPID-3 Study, please contact your study team:
RAPID-3 Flyer Version 1.0 25 March 2025

*Investigational device: Limited by United States law to investigational use.